Although previous studies have discussed the efficacy of MM treatment with Met and/or NF-κB inhibitors, this study demonstrates a clear application for Met and NF-κB inhibitors in treating HGF-related bone disease in MM patients. Here, NFKB1 is linked to Miyoshi myopathy.